HIGHLIGHTS
- who: Lea Bentur and Mordechai Pollak from the (UNIVERSITY) have published the paper: Trikaftau2014Extending Its Success to Less Common Mutations, in the Journal: (JOURNAL) of 13/09/2022
SUMMARY
Various modulators and correctors have been developed based on the specific genotype and class of CFTR; hence, they represent a model of personalized medicine. The breakthrough in attitudes toward individualized therapy in CF has been further advanced by the development of in_vitro models to predict responses to therapy; this has led to an innovative approach by the FDA of extending the approval of modulators . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.